ABBV-576
- Generic Name
- ABBV-576
A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT05530278
- Locations
- 🇺🇸
Anaheim Clinical Trials LLC /ID# 248824, Anaheim, California, United States
🇺🇸Clinical Pharmacology of Miami /ID# 248823, Miami, Florida, United States
🇺🇸PPD Clinical Research Unit -Las Vegas /ID# 248853, Las Vegas, Nevada, United States
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis
Phase 2
Terminated
- Conditions
- Cystic Fibrosis (CF)
- Interventions
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 48
- Registration Number
- NCT04853368
- Locations
- 🇺🇸
University of Southern California /ID# 249147, Los Angeles, California, United States
🇺🇸UH Cleveland Medical Center /ID# 245433, Cleveland, Ohio, United States
🇺🇸Boston Children's Hospital /ID# 248646, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath